PetVivo Holdings (PETV)
OTHER OTC:PETV
PETV Stock Chart & Stats
$1.12
$0.00(0.00%)
At close: 4:00 PM EST
$1.12
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.45 - $1.69
Previous CloseN/A
Volume249.00
Average Volume (3M)21.60K
Market Cap
$25.74M
Enterprise Value$19.99M
Total Cash (Recent Filing)$168.16K
Total Debt (Recent Filing)$70.56K
Price to Earnings (P/E)―
Beta0.09
Next Earnings
Jun 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding35,017,418
10 Day Avg. Volume14,407
30 Day Avg. Volume21,604
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)2.91
Price to Sales (P/S)10.86
P/FCF Ratio-2.09
Enterprise Value/Market Cap0.78
Enterprise Value/Revenue17.98
Enterprise Value/Gross Profit27.22
Enterprise Value/Ebitda-2.54
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Exclusive AI License & High‑margin SaaSA secured 10-year white‑label license and B2B SaaS launch create a structurally different, recurring revenue stream with very high gross margins and low incremental CapEx. If executed, PetVivo AI can diversify revenue away from one‑time device sales and materially improve long‑term unit economics and cash conversion.
Distribution Partnerships & International ExpansionLarge channel deals and initial international distributors expand the addressable market and offer scalable adoption pathways for SPRYNG and PrecisePRP. Broadening clinic reach reduces reliance on direct sales, supports steady replenishment demand, and strengthens commercialization durability across regions.
Material Reduction In Liabilities; Low LeverageAn ~81% cut in liabilities and minimal debt reduce near-term solvency risk and interest burden, giving management runway to prioritize commercialization and product launches. Lower leverage improves financial flexibility for executing AI rollout and clinical programs without immediate refinancing pressure.
Bears Say
Sustained Negative Cash FlowPersistent multi‑million-dollar operating and free cash outflows indicate the business currently consumes cash faster than it generates it. That ongoing burn constrains investment in sales and R&D, increases dependency on external funding, and elevates execution risk until recurring SaaS inflows or improved margins materialize.
Deep Unprofitability And Revenue DeclineA steep revenue decline combined with extremely negative net margins shows core operations are not producing sustainable returns. Even with solid gross margins, outsized operating expenses overwhelm the business, requiring meaningful revenue scale or structural cost reductions to reach profitability over the medium term.
Dilution Risk And Tight LiquidityOngoing reliance on dilutive equity financings to fund operations, combined with modest working capital, creates structural shareholder dilution risk and governance tradeoffs. Continued raises could compress per‑share economics unless new high‑margin SaaS revenue ramps sufficiently to reduce external funding needs.
PetVivo Holdings News
PETV FAQ
What was PetVivo Holdings’s price range in the past 12 months?
PetVivo Holdings lowest stock price was $0.45 and its highest was $1.69 in the past 12 months.
What is PetVivo Holdings’s market cap?
PetVivo Holdings’s market cap is $25.74M.
When is PetVivo Holdings’s upcoming earnings report date?
PetVivo Holdings’s upcoming earnings report date is Jun 25, 2026 which is in 89 days.
How were PetVivo Holdings’s earnings last quarter?
PetVivo Holdings released its earnings results on Feb 17, 2026. The company reported -$0.069 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.069.
Is PetVivo Holdings overvalued?
According to Wall Street analysts PetVivo Holdings’s price is currently Overvalued.
Does PetVivo Holdings pay dividends?
PetVivo Holdings does not currently pay dividends.
What is PetVivo Holdings’s EPS estimate?
PetVivo Holdings’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PetVivo Holdings have?
PetVivo Holdings has 35,017,418 shares outstanding.
What happened to PetVivo Holdings’s price movement after its last earnings report?
PetVivo Holdings reported an EPS of -$0.069 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.881%.
Which hedge fund is a major shareholder of PetVivo Holdings?
Currently, no hedge funds are holding shares in PETV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PetVivo Holdings
PetVivo Holdings, Inc., a biomedical device company, engages in the manufacturing, commercializing, and licensing of medical devices and biomaterials for the treatment of afflictions and diseases in animals. Its lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. The company's pipeline products also include 17 therapeutic devices for veterinary and human clinical applications. PetVivo Holdings, Inc. was founded in 2009 and is headquartered in Minneapolis, Minnesota.
PETV Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a strongly positive strategic and operational narrative: management secured transformative partnerships (exclusive AI licensing, major distributor and channel agreements), advanced R&D and international commercialization (Health Canada recognition, U.K. and Mexico distribution), and materially reduced liabilities (≈81% decline). These developments position the company for a recurring, high-margin SaaS revenue stream (PetVivo AI) that could complement device and biologic sales. Near-term financials remain challenging — modest revenue decline (−2% YoY for nine months), lower gross margins from product mix, ongoing operating losses (net loss $7.5M) and cash burn ($5.3M) leave liquidity and timing risks. Overall, the strategic progress and balance sheet improvements outweigh the current financial headwinds, suggesting a Positive sentiment with execution and monetization of AI and commercialization plans as key drivers to watch.View all PETV earnings summariesTechnical Analysis
Iridex
―
Lifeward
―
Vivos Therapeutics
―
Allurion Technologies
―
Nexalin Technology, Inc.
―
Ownership Overview
40.48% Insiders
0.37% Other Institutional Investors
59.15% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---